动脉粥样硬化与炎症关系的研究进展。
Research Progress on the Relationship between Atherosclerosis and Inflammation.
机构信息
Laboratory Animal Center, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China.
出版信息
Biomolecules. 2018 Aug 23;8(3):80. doi: 10.3390/biom8030080.
Abstract
Atherosclerosis is a chronic inflammatory disease; unstable atherosclerotic plaque rupture, vascular stenosis, or occlusion caused by platelet aggregation and thrombosis lead to acute cardiovascular disease. Atherosclerosis-related inflammation is mediated by proinflammatory cytokines, inflammatory signaling pathways, bioactive lipids, and adhesion molecules. This review discusses the effects of inflammation and the systemic inflammatory signaling pathway on atherosclerosis, the role of related signaling pathways in inflammation, the formation of atherosclerosis plaques, and the prospects of treating atherosclerosis by inhibiting inflammation.
摘要
动脉粥样硬化是一种慢性炎症性疾病；不稳定的动脉粥样硬化斑块破裂、血小板聚集和血栓形成导致血管狭窄或闭塞，进而引发急性心血管疾病。与动脉粥样硬化相关的炎症是由促炎细胞因子、炎症信号通路、生物活性脂质和黏附分子介导的。本文综述了炎症和系统性炎症信号通路对动脉粥样硬化的影响、相关信号通路在炎症、动脉粥样硬化斑块形成中的作用，以及通过抑制炎症治疗动脉粥样硬化的前景。
相似文献
1
Research Progress on the Relationship between Atherosclerosis and Inflammation.动脉粥样硬化与炎症关系的研究进展。
Biomolecules. 2018 Aug 23;8(3):80. doi: 10.3390/biom8030080.
2
The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.秋水仙碱通过抗炎和降低高甘油三酯血症对动脉粥样硬化的有益治疗作用。
Cardiovasc Hematol Agents Med Chem. 2018;16(2):74-80. doi: 10.2174/1871525717666181211110332.
3
Potential of anti-inflammatory agents for treatment of atherosclerosis.抗炎药物治疗动脉粥样硬化的潜力。
Exp Mol Pathol. 2018 Apr;104(2):114-124. doi: 10.1016/j.yexmp.2018.01.008. Epub 2018 Jan 31.
4
Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease.基于该疾病炎症和增殖方面的抗动脉粥样硬化疗法的开发。
Curr Pharm Des. 2015;21(9):1196-204. doi: 10.2174/1381612820666141013150714.
5
Atherosclerosis, Periodontal Disease, and Treatment with Resolvins.动脉粥样硬化、牙周病与 resolvins 的治疗。
Curr Atheroscler Rep. 2017 Nov 6;19(12):57. doi: 10.1007/s11883-017-0696-4.
6
Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway.动脉粥样硬化 Toll 样受体通路作用机制及药物治疗的研究进展。
J Cardiovasc Pharmacol. 2019 Nov;74(5):379-388. doi: 10.1097/FJC.0000000000000738.
7
Targeting inflammation in cardiovascular diseases. still a neglected field?靶向治疗心血管疾病中的炎症反应。这一领域仍被忽视？
Cardiovasc Ther. 2012 Aug;30(4):e189-97. doi: 10.1111/j.1755-5922.2011.00274.x. Epub 2011 Apr 1.
8
Inflammation in atherosclerosis: transition from theory to practice.动脉粥样硬化中的炎症：从理论到实践的转变。
Circ J. 2010 Feb;74(2):213-20. doi: 10.1253/circj.cj-09-0706. Epub 2010 Jan 9.
9
The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease.炎症生物标志物在动脉粥样硬化疾病检测与治疗中的作用
Curr Vasc Pharmacol. 2016;14(6):534-546. doi: 10.2174/1570161114666160625080104.
10
The Characteristics and Roles of Advanced Oxidation Protein Products in Atherosclerosis.晚期氧化蛋白产物在动脉粥样硬化中的特征与作用
Cardiovasc Toxicol. 2017 Jan;17(1):1-12. doi: 10.1007/s12012-016-9377-8.
引用本文的文献
1
Non-Skeletal Roles of Vitamin D in Skin, Gut, and Cardiovascular Disease: Focus on Epithelial Barrier Function and Immune Regulation in Chronic Disease.维生素D在皮肤、肠道及心血管疾病中的非骨骼作用：聚焦于慢性病中的上皮屏障功能和免疫调节
Int J Mol Sci. 2025 Sep 2;26(17):8520. doi: 10.3390/ijms26178520.
2
The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study.载脂蛋白A-I水平与慢性心力衰竭患者尤其是射血分数保留的心力衰竭（HFpEF）和射血分数中间值的心力衰竭（HFmrEF）患者的预后相关：一项回顾性队列研究。
Int J Gen Med. 2025 Aug 25;18:4735-4751. doi: 10.2147/IJGM.S531156. eCollection 2025.
3
Bacterial Extracellular Vesicles: Emerging Regulators in the Gut-Organ Axis and Prospective Biomedical Applications.细菌细胞外囊泡：肠道-器官轴中的新兴调节因子及潜在生物医学应用
Curr Microbiol. 2025 Sep 1;82(10):486. doi: 10.1007/s00284-025-04474-w.
4
Nutritional-inflammatory balance assessed by advanced lung cancer inflammation index and its association with all-cause mortality in coronary heart disease : a retrospective cohort study.通过晚期肺癌炎症指数评估的营养-炎症平衡及其与冠心病全因死亡率的关联：一项回顾性队列研究
J Health Popul Nutr. 2025 Aug 31;44(1):317. doi: 10.1186/s41043-025-01063-2.
5
Epithelial sodium channel in dendritic cells participates in high-fat-induced inflammatory responses.树突状细胞中的上皮钠通道参与高脂诱导的炎症反应。
Mol Biol Rep. 2025 Aug 30;52(1):856. doi: 10.1007/s11033-025-10959-5.
6
S-Nitrosylation in Cardiovascular Disorders: The State of the Art.心血管疾病中的S-亚硝基化：最新进展
Biomolecules. 2025 Jul 24;15(8):1073. doi: 10.3390/biom15081073.
7
Platelet RNA-Seq Reveals Genes Associated with Carotid Intima-Media Thickness: A Cross-Sectional Study.血小板RNA测序揭示与颈动脉内膜中层厚度相关的基因：一项横断面研究。
TH Open. 2025 Aug 7;9:a26616472. doi: 10.1055/a-2661-6472. eCollection 2025.
8
SPTBN1 overexpression ameliorates atherosclerosis by inhibiting oxidative stress and inflammation via regulating the TRIM37/TRAF2/NF-κB pathway.SPTBN1过表达通过调节TRIM37/TRAF2/NF-κB途径抑制氧化应激和炎症来改善动脉粥样硬化。
Eur J Med Res. 2025 Aug 21;30(1):781. doi: 10.1186/s40001-025-02994-6.
9
Heqi San alleviates diabetic atherosclerosis and alters serum metabolic profiles in rats.和剂散减轻大鼠糖尿病性动脉粥样硬化并改变血清代谢谱。
BMC Cardiovasc Disord. 2025 Aug 18;25(1):610. doi: 10.1186/s12872-025-05012-z.
10
Association of matrix metalloproteinases and adhesive molecules with important aspects of carotid artery stenosis.基质金属蛋白酶和黏附分子与颈动脉狭窄重要方面的关联
J Med Biochem. 2025 Jun 13;44(3):553-560. doi: 10.5937/jomb0-51391.
本文引用的文献
1
Contribution of TLR4 signaling in intermittent hypoxia-mediated atherosclerosis progression.TLR4 信号通路在间歇性低氧介导的动脉粥样硬化进展中的作用。
J Transl Med. 2018 Apr 19;16(1):106. doi: 10.1186/s12967-018-1479-6.
2
C-Reactive Protein in Atherothrombosis and Angiogenesis.C 反应蛋白在动脉粥样血栓形成和血管生成中的作用。
Front Immunol. 2018 Mar 2;9:430. doi: 10.3389/fimmu.2018.00430. eCollection 2018.
3
Potential of anti-inflammatory agents for treatment of atherosclerosis.抗炎药物治疗动脉粥样硬化的潜力。
Exp Mol Pathol. 2018 Apr;104(2):114-124. doi: 10.1016/j.yexmp.2018.01.008. Epub 2018 Jan 31.
4
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.在稳定性冠心病中炎症生物标志物白细胞介素-6 和 C 反应蛋白与结局：来自 STABILITY（通过起始达泊利德治疗稳定动脉粥样硬化斑块）试验的经验。
J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
5
A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.系统比较靶向炎症性动脉粥样硬化中 HMG-CoA 还原酶的临床可行纳米药物。
J Control Release. 2017 Sep 28;262:47-57. doi: 10.1016/j.jconrel.2017.07.013. Epub 2017 Jul 9.
6
Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.超敏C反应蛋白与全因、心血管及癌症死亡风险：一项荟萃分析。
Atherosclerosis. 2017 Apr;259:75-82. doi: 10.1016/j.atherosclerosis.2017.02.003. Epub 2017 Feb 9.
7
Integrin signaling in atherosclerosis.动脉粥样硬化中的整合素信号传导
Cell Mol Life Sci. 2017 Jun;74(12):2263-2282. doi: 10.1007/s00018-017-2490-4. Epub 2017 Feb 28.
8
Sargachromenol protects against vascular inflammation by preventing TNF-α-induced monocyte adhesion to primary endothelial cells via inhibition of NF-κB activation.Sargachromenol 通过抑制 NF-κB 激活来防止 TNF-α 诱导的单核细胞黏附至原代内皮细胞，从而起到防止血管炎症的作用。
Int Immunopharmacol. 2017 Jan;42:81-89. doi: 10.1016/j.intimp.2016.11.014. Epub 2016 Nov 27.
9
mCRP triggers angiogenesis by inducing F3 transcription and TF signalling in microvascular endothelial cells.修饰性C反应蛋白通过诱导微血管内皮细胞中的F3转录和组织因子信号传导来触发血管生成。
Thromb Haemost. 2017 Jan 26;117(2):357-370. doi: 10.1160/TH16-07-0524. Epub 2016 Nov 3.
10
The critical role of ABCG1 and PPARγ/LXRα signaling in TLR4 mediates inflammatory responses and lipid accumulation in vascular smooth muscle cells.ABCG1和PPARγ/LXRα信号通路在Toll样受体4（TLR4）介导的血管平滑肌细胞炎症反应和脂质积累中起关键作用。
Cell Tissue Res. 2017 Apr;368(1):145-157. doi: 10.1007/s00441-016-2518-3. Epub 2016 Nov 2.
Zotero 插件